Debbie Moreton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Debbie Moreton has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bozena Katic
Communicable Disease Service, New Jersey Department of Health , Trenton, New Jersey
3 shared publications - John Ko
Novartis Pharmceuticals Corp. East Hanover NJ United States
3 shared publications - Kristina Simacek
PatientsLikeMe, Cambridge, MA, USA
3 shared publications - Stefan Varga
WorldWide Medical Immunology, Bristol Myers Squibb, Princeton, New Jersey, USA
3 shared publications - Kristen Johnson
Novartis Pharmaceuticals Corporation
2 shared publications Nicole Buechler
PatientsLikeMe Cambridge MA United States
1 shared publication
Latest Publications
- Open Access
- 30 October 2018
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 20 (10) , e11168
The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: In the United States, relapsing-remitting multiple sclerosis (RRMS) patients can face difficulty accessing disease-modifying therapies (DMTs) due to insurance, pharmacy, or provider policies. These barriers have been associated with poor adherence and negative health outcomes. Objective: The goals of the current study were to describe the overall occurrence of difficulties and delays associated with gaining access to DMTs among patients with RRMS, to assess DMT adherence during periods of reduced access, and to contextualize the patient journey from receipt of a prescription for DMT to obtaining and taking their medication when faced with access barriers. Methods: U.S.-based adult patients self-reporting RRMS were recruited from an online health data-sharing social network, PatientsLikeMe. Patients were invited to complete a web-based survey if they reported a diagnosis of RRMS and were prescribed a DMT for MS. Follow-up phone interviews were conducted with 10 respondents who reported experiencing a MS-related relapse during the time they had experienced challenges accessing DMTs. Results: Among 507 survey completers, nearly half were either currently experiencing an issue related to DMT assess or had difficulty accessing a DMT in the past (233/507, 46.0%). The most frequently reported reasons related to access difficulty were authorization requirements by insurance (78/182, 42.9% for past issues and 9/42, 21% for current issues) and high out-of-pocket costs (54/182, 29.7% for past issues and 13/42, 31% for current issues). About half (51%) of patients with current access issues and over a third (38%) of those with past issues went without their medication until they could access their prescribed DMT. Relapses were reported during periods of reduced DMT access for nearly a third (56/118, 29.8%) of those with past issues and nearly half (22/45, 49%) of those with current issues. Resolving access issues involved multiple stakeholder agents often coordinated in a patient-led effort. Among those who had resolved issues, about half (57/119, 47.9%) reported that doctors/office staff were involved, under half (48/119, 40.3%) were involved themselves, and about a third (39/119, 32.8%) reported the drug manufacturer was involved in resolving the issue. Follow-up interviews revealed that the financial burden associated with obtaining a prescribed DMT led to non-adherence. Additionally, patients felt that DMT treatment delays and stress associated with obtaining the DMT triggered relapses or worsened their MS. Conclusions: This study expands current research by using a patient-centered, mixed-methods approach to describe the patient perspective on barriers to MS treatment, process to resolve barriers, and the perceived impact of treatment barriers on outcomes. Issues related to DMT access occur frequently, with patients often serving as their own agents when navigating access difficulties to obtain their medication(s). Patient support for resolution of DMT access is needed to prevent undue stress and nonadherence.
- 30 October 2018
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 20 (10) , e11168
Open AccessThe Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: In the United States, relapsing-remitting multiple sclerosis (RRMS) patients can face difficulty accessing disease-modifying therapies (DMTs) due to insurance, pharmacy, or provider policies. These barriers have been associated with poor adherence and negative health outcomes. Objective: The goals of the current study were to describe the overall occurrence of difficulties and delays associated with gaining access to DMTs among patients with RRMS, to assess DMT adherence during periods of reduced access, and to contextualize the patient journey from receipt of a prescription for DMT to obtaining and taking their medication when faced with access barriers. Methods: U.S.-based adult patients self-reporting RRMS were recruited from an online health data-sharing social network, PatientsLikeMe. Patients were invited to complete a web-based survey if they reported a diagnosis of RRMS and were prescribed a DMT for MS. Follow-up phone interviews were conducted with 10 respondents who reported experiencing a MS-related relapse during the time they had experienced challenges accessing DMTs. Results: Among 507 survey completers, nearly half were either currently experiencing an issue related to DMT assess or had difficulty accessing a DMT in the past (233/507, 46.0%). The most frequently reported reasons related to access difficulty were authorization requirements by insurance (78/182, 42.9% for past issues and 9/42, 21% for current issues) and high out-of-pocket costs (54/182, 29.7% for past issues and 13/42, 31% for current issues). About half (51%) of patients with current access issues and over a third (38%) of those with past issues went without their medication until they could access their prescribed DMT. Relapses were reported during periods of reduced DMT access for nearly a third (56/118, 29.8%) of those with past issues and nearly half (22/45, 49%) of those with current issues. Resolving access issues involved multiple stakeholder agents often coordinated in a patient-led effort. Among those who had resolved issues, about half (57/119, 47.9%) reported that doctors/office staff were involved, under half (48/119, 40.3%) were involved themselves, and about a third (39/119, 32.8%) reported the drug manufacturer was involved in resolving the issue. Follow-up interviews revealed that the financial burden associated with obtaining a prescribed DMT led to non-adherence. Additionally, patients felt that DMT treatment delays and stress associated with obtaining the DMT triggered relapses or worsened their MS. Conclusions: This study expands current research by using a patient-centered, mixed-methods approach to describe the patient perspective on barriers to MS treatment, process to resolve barriers, and the perceived impact of treatment barriers on outcomes. Issues related to DMT access occur frequently, with patients often serving as their own agents when navigating access difficulties to obtain their medication(s). Patient support for resolution of DMT access is needed to prevent undue stress and nonadherence.
- Open Access
- 29 May 2018
- Published by JMIR Publications Inc. in JMIR Preprints
The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study (Preprint)
BACKGROUND In the United States, people with relapsing-remitting multiple sclerosis (RRMS) can face difficulty accessing disease-modifying therapies (DMTs) because of insurance, pharmacy, or provider policies. These barriers have been associated with poor adherence and negative health outcomes. OBJECTIVE The goals of this study were to describe the overall occurrence of difficulties and delays associated with gaining access to DMTs among people with RRMS, to assess DMT adherence during periods of reduced access, and to contextualize the patients’ journey from receipt of a prescription for DMT to obtaining and taking their medication when faced with access barriers. METHODS We recruited US-based adults self-reporting RRMS from a Web-based health data-sharing social network, PatientsLikeMe. Individuals were invited to complete a Web-based survey if they reported a diagnosis of RRMS and were prescribed a DMT for MS. Follow-up phone interviews were conducted with 10 respondents who reported experiencing an MS-related relapse during the time they had experienced challenges accessing DMTs. RESULTS Among 507 survey completers, nearly half were either currently experiencing an issue related to DMT assess or had difficulty accessing a DMT in the past (233/507, 46.0%). The most frequently reported reasons for access difficulty were authorization requirements by insurance companies (past issues: 78/182, 42.9%; current issues: 9/42, 21%) and high out-of-pocket costs (past issues: 54/182, 29.7%; current issues: 13/42, 31%). About half (20/39, 51%) of participants with current access issues and over a third (68/165, 41.2%) of those with past issues went without their medication until they could access their prescribed DMT. Relapses were reported during periods of reduced DMT access for almost half (56/118, 47.5%) of those with past issues and nearly half (22/45, 49%) of those with current issues. Resolving access issues involved multiple stakeholder agents often coordinated in a patient-led effort. Among those who had resolved issues, about half (57/119, 47.9%) reported that doctors or office staff were involved, under half (48/119, 40.3%) were involved themselves, and about a third (39/119, 32.8%) reported the drug manufacturer was involved in resolving the issue. Follow-up interviews revealed that the financial burden associated with obtaining a prescribed DMT led to nonadherence. Additionally, participants felt that DMT treatment delays and stress associated with obtaining the DMT triggered relapses or worsened their MS. CONCLUSIONS This study expands current research by using a patient-centered, mixed-methods approach to describe barriers to MS treatment, the process to resolve barriers, and the perceived impact of treatment barriers on outcomes. Issues related to DMT access occur frequently, with individuals often serving as their own agents when navigating access difficulties to obtain their medication(s). Support for resolution of DMT access is needed to prevent undue stress and nonadherence.
- 29 May 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study (Preprint)
BACKGROUND In the United States, people with relapsing-remitting multiple sclerosis (RRMS) can face difficulty accessing disease-modifying therapies (DMTs) because of insurance, pharmacy, or provider policies. These barriers have been associated with poor adherence and negative health outcomes. OBJECTIVE The goals of this study were to describe the overall occurrence of difficulties and delays associated with gaining access to DMTs among people with RRMS, to assess DMT adherence during periods of reduced access, and to contextualize the patients’ journey from receipt of a prescription for DMT to obtaining and taking their medication when faced with access barriers. METHODS We recruited US-based adults self-reporting RRMS from a Web-based health data-sharing social network, PatientsLikeMe. Individuals were invited to complete a Web-based survey if they reported a diagnosis of RRMS and were prescribed a DMT for MS. Follow-up phone interviews were conducted with 10 respondents who reported experiencing an MS-related relapse during the time they had experienced challenges accessing DMTs. RESULTS Among 507 survey completers, nearly half were either currently experiencing an issue related to DMT assess or had difficulty accessing a DMT in the past (233/507, 46.0%). The most frequently reported reasons for access difficulty were authorization requirements by insurance companies (past issues: 78/182, 42.9%; current issues: 9/42, 21%) and high out-of-pocket costs (past issues: 54/182, 29.7%; current issues: 13/42, 31%). About half (20/39, 51%) of participants with current access issues and over a third (68/165, 41.2%) of those with past issues went without their medication until they could access their prescribed DMT. Relapses were reported during periods of reduced DMT access for almost half (56/118, 47.5%) of those with past issues and nearly half (22/45, 49%) of those with current issues. Resolving access issues involved multiple stakeholder agents often coordinated in a patient-led effort. Among those who had resolved issues, about half (57/119, 47.9%) reported that doctors or office staff were involved, under half (48/119, 40.3%) were involved themselves, and about a third (39/119, 32.8%) reported the drug manufacturer was involved in resolving the issue. Follow-up interviews revealed that the financial burden associated with obtaining a prescribed DMT led to nonadherence. Additionally, participants felt that DMT treatment delays and stress associated with obtaining the DMT triggered relapses or worsened their MS. CONCLUSIONS This study expands current research by using a patient-centered, mixed-methods approach to describe barriers to MS treatment, the process to resolve barriers, and the perceived impact of treatment barriers on outcomes. Issues related to DMT access occur frequently, with individuals often serving as their own agents when navigating access difficulties to obtain their medication(s). Support for resolution of DMT access is needed to prevent undue stress and nonadherence.
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Multiple sclerosis patient experiences with access to disease-modifying therapies: A qualitative analysis on the patient impact of medication access barriers (P3.333)
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Multiple sclerosis patient experiences with access to disease-modifying therapies: A qualitative analysis on the patient impact of medication access barriers (P3.333)